D L Carlson Investment Group Inc. Invests $1.71 Million in IDEXX Laboratories, Inc. $IDXX

D L Carlson Investment Group Inc. purchased a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the second quarter, HoldingsChannel reports. The firm purchased 3,193 shares of the company’s stock, valued at approximately $1,713,000.

A number of other institutional investors and hedge funds have also bought and sold shares of IDXX. Vanguard Group Inc. lifted its stake in shares of IDEXX Laboratories by 1.5% in the first quarter. Vanguard Group Inc. now owns 9,855,937 shares of the company’s stock worth $4,139,001,000 after buying an additional 146,427 shares in the last quarter. Geode Capital Management LLC increased its position in shares of IDEXX Laboratories by 2.3% during the second quarter. Geode Capital Management LLC now owns 2,464,290 shares of the company’s stock valued at $1,317,875,000 after acquiring an additional 54,402 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in IDEXX Laboratories by 71.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,988,912 shares of the company’s stock worth $835,244,000 after acquiring an additional 825,965 shares during the last quarter. Bank of New York Mellon Corp lifted its position in IDEXX Laboratories by 156.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company’s stock valued at $778,439,000 after acquiring an additional 884,808 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in IDEXX Laboratories by 0.5% during the 1st quarter. Invesco Ltd. now owns 1,166,406 shares of the company’s stock valued at $489,832,000 after purchasing an additional 5,418 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Weiss Ratings restated a “hold (c+)” rating on shares of IDEXX Laboratories in a research note on Tuesday, November 25th. Wall Street Zen lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday. JPMorgan Chase & Co. raised their price target on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Morgan Stanley lifted their price target on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Finally, BTIG Research increased their price objective on shares of IDEXX Laboratories from $785.00 to $830.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Seven research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $730.50.

Insider Transactions at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the sale, the executive vice president directly owned 21,149 shares of the company’s stock, valued at approximately $14,874,937.66. This represents a 30.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories Trading Down 3.2%

NASDAQ:IDXX opened at $728.97 on Tuesday. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98. The business has a fifty day moving average price of $668.65 and a 200-day moving average price of $607.93. The firm has a market capitalization of $58.21 billion, a price-to-earnings ratio of 60.70, a price-to-earnings-growth ratio of 4.06 and a beta of 1.62. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.08. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the previous year, the company posted $2.80 earnings per share. IDEXX Laboratories’s revenue for the quarter was up 13.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.